SCHEMBL223653

SCHEMBL223653

COC(=O)CCc1ccc(N)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.50
CYP4A11 Q02928 2/20 0.50
F2RL1 P55085 1/20 0.49
GFER P55789 2/20 0.48
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
IDO1 P14902 1/20 0.47
CYP19A1 P11511 2/20 0.46
EPHX2 P34913 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
F2 P00734 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7282073 0.98 CYP4F2 (0.49) CYP4F2CYP4A11F2RL1GFERADRB2
Sulfuric Acid SCHEMBL4181579 0.93 IDO1 (0.49) CYP4F2CYP4A11F2RL1GFERADRB2
SCHEMBL22922181 0.90 CYP4F2 (0.59) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL1351101 0.89 TSHR (0.48) CYP4F2CYP4A11GFERCYP19A1EPHX2
SCHEMBL1745141 0.87 FFAR1 (0.58) ADRB2ADRB1ALDH1A1MAPTHTT
Hydrochloric Acid SCHEMBL1789073 0.87 MAOB (0.47) CYP4F2CYP4A11GFERCYP19A1EPHX2
SCHEMBL9689657 0.87 MAOB (0.48) CYP4F2CYP4A11EPHX2TSHR
SCHEMBL28813051 0.87 F2RL1 (0.57) CYP4F2CYP4A11F2RL1GFERCYP19A1
Hydrochloric Acid SCHEMBL9265296 0.87 TAAR1 (0.50) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL23200335 0.86 HPGD (0.49) CYP4F2CYP4A11EPHX2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3099728-A1 COPOLYMER OF A BISPHENOL DIGLYCIDYL ETHER AND A PHENOLPHTHALENE AND/OR A PHENOLPHTHALIMIDINE, METHOD FOR THE PREPARATION THEREOF, ARTICLE COMPRISING THE COPOLYMER, AND COMPOSITIONS COMPRISING THE COPOLYMER SABIC Global Technologies B.V. (NL) 2016-12-07 EP claimed
EP-2951226-A1 TRIBLOCK COPOLYMER, METHOD FOR ITS FORMATION, AND COMPATIBILIZED COMPOSITIONS COMPRISING IT SABIC Global Technologies B.V. (NL) 2015-12-09 EP claimed
WO-2015116349-A1 COPOLYMER OF A BISPHENOL DIGLYCIDYL ETHER AND A PHENOLPHTHALENE AND/OR A PHENOLPHTHALIMIDINE, METHOD FOR THE PREPARATION THEREOF, ARTICLE COMPRISING THE COPOLYMER, AND COMPOSITIONS COMPRISING THE COPOLYMER SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2015-08-06 WO claimed
US-20150210806-A1 COPOLYMER OF A BISPHENOL DIGLYCIDYL ETHER AND A PHENOLPHTHALENE AND/OR A PHENOLPHTHALIMIDINE, METHOD FOR THE PREPARATION THEREOF, ARTICLE COMPRISING THE COPOLYMER, AND COMPOSITIONS COMPRISING THE COPOLYMER SHPP GLOBAL TECHNOLOGIES B.V. (NL) 2015-07-30 US claimed
EP-2822998-A1 COMPATIBILIZED COMPOSITION, METHOD FOR THE FORMATION THEREOF, AND ARTICLE COMPRISING SAME SABIC Innovative Plastics IP B.V. (NL) 2015-01-14 EP claimed
US-8865823-B2 Triblock copolymer, method for its formation, and compatibilized compositions comprising it SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2014-10-21 US claimed
US-20140221552-A1 TRIBLOCK COPOLYMER, METHOD FOR ITS FORMATION, AND COMPATIBILIZED COMPOSITIONS COMPRISING IT SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2014-08-07 US claimed
WO-2014120650-A1 TRIBLOCK COPOLYMER, METHOD FOR ITS FORMATION, AND COMPATIBILIZED COMPOSITIONS COMPRISING IT SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2014-08-07 WO claimed
US-8552105-B2 Compatibilized composition, method for the formation thereof, and article comprising same SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2013-10-08 US claimed
US-20130237648-A1 COMPATIBILIZED COMPOSITION, METHOD FOR THE FORMATION THEREOF, AND ARTICLE COMPRISING SAME SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2013-09-12 US claimed
WO-2013133878-A1 COMPATIBILIZED COMPOSITION, METHOD FOR THE FORMATION THEREOF, AND ARTICLE COMPRISING SAME SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2013-09-12 WO claimed
WO-2025122555-A1 S1P 1 RECEPTOR AGONISTS AND USES THEREOF VALO HEALTH, INC. (US) 2025-06-12 WO disclosed
US-20250066364-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2025-02-27 US disclosed
US-20240398776-A1 INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS NEXYS THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024211969-A1 PPARG MODULATORS Setonix Pharmaceuticals Pty Ltd (AU) 2024-10-17 WO disclosed
CN-1048039-A Imidazolyl-alkenoic acids SMITHKLINE BEECHAM CORP (US) 1990-12-26 CN disclosed
EP-0271099-A2 Substituted aminopropionic acid amides, process for their preparation, agents containing them and their use as well as the intermediates formed during the preparation HOECHST AKTIENGESELLSCHAFT (DE) 1988-06-15 EP disclosed
US-4456668-A DYE BLEACH, TEXTILE DYES CIBA GEIGY AG (CH) 1984-06-26 US disclosed
US-4409143-A TEXTILES, PHOTOGRAPHY CIBA-GEIGY AG (CH) 1983-10-11 US disclosed
US-4379819-A OIL SOLUBLE MONOAZO DYE CIBA-GEIGY AG (CH) 1983-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240398776-A1 INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS ACVR1, TGFBR1, ACVRL1 CYP4F2 4382/4885CYP4A11 2756/4885F2RL1 385/4885
US-20250066364-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS PARK7, PNP, GAA CYP4F2 3971/4885CYP4A11 2403/4885F2RL1 4027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.